Trial Profile

Tozinameran COVID-19 Vaccine Safety Surveillance Program assessing safety

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozinameran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

06 Sep 2022 New trial record
30 Aug 2022 According to a Analysis Group's media release, Dr. Maral DerSarkissian and Dr. Mei Sheng Duh are co-investigators for this trial.
30 Aug 2022 According to a Analysis Group's media release, researchers from Analysis Group (a global leader in health care consulting), the Veterans Health Administration (VHA), and Pfizer presented interim results from this trial During the International Society of Pharmacoepidemiology's annual meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com